Genmab — Juni 2018
-
Den konkrete pen, der skal bruges, er tilsyneladende ikke på markedet endnu. Formentlig noget helt nyt, pga de udfordringer der har været med pen-injektioner og mAbs høje viskositet https://www.sciencedirect.com/topics/medicine-and-dentistry/autoinjector
-
-
-
Bibob> Burde det ikke have haft en positiv effekt på Genmabs kurs i dag?
-
Den er jeg med på. Men direkte kurspåvirkende nyheder, plejer trods alt at rykke Genmab pænt opad. Bluebird falder også “kun” 3 %.
-
Medicinrådet har ikke opdateret hjemmesiden endnu. http://www.medicinraadet.dk/igangvaerende-vurderinger/ansoegninger-under-behandling/ocrelizumab-ocrevus-attakvis-multipel-sklerose
-
-
Faldt lige over denne her: Plus og minus ved car-t http://onkologisktidsskrift.dk/behandlinger/785-t-celleterapiens-udfordring-er-at-finde-de-rette-modtagere.html
-
Drs. Brian GM Durie, Joseph Mikhael, and Sagar Lonial discusses CAR T-cell therapy in multiple myeloma - https://www.myeloma.org/videos/stockholm-2018-car-t-cell-therapy-0
-
https://twitter.com/search?f=tweets&vertical=default&q=myeloma&src=savs nice slide on Dara development. Would be nice to see that presentation
-
-
Yes and it is down 1%. Do you Think it is a coincidence regarding the volume? Maybe
it has somerhing to do with the upcoming numbers on wednesday.
The volumen is nothing compared to CPH and dont conclude anything !Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind